Home > Inhibitors & Agonists > Immunology/Inflammation > IRAK
Cat. No. Product name CAS No.
DC11497 IRAK4-IN-28

A novel potent, selective IRAK4 inhibitor with IC50 of 51 nM.

2196204-23-4
DC10648 CA4948-Analog Featured

CA4948-Analog is an analog of Emavusertib. It has similar property to CA-4948, which is a potent, and orally active interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor. It was reported in patent WO 2015104688. Emavusertib, also known as CA-4948 is a potent IRAK4/FLT3 inhibitor with anti-tumor activity. CA-4948 demonstrated good cellular activity in ABC DLBCL and AML cell lines. CA-4948 demonstrated moderate to high selectivity in a panel of 329 kinases as well as exhibited desirable ADME and PK profiles including good oral bioavailability in mice, rat, and dog and showed >90% tumor growth inhibition in relevant tumor models with excellent correlation with in vivo PD modulation.

1801343-74-7
DC8328 IRAK-1/4 Inhibitor Featured

Interleukin-1 Receptor-Associated-Kinase-1/4 Inhibitor is a benzimidazole compound that acts as a cell-permeable, potent selective inhibitor of IL-1 kinases.

509093-47-4
DC9491 IRAK inhibitor 1 Featured

IRAK inhibitor 1 is an interleukin-1 receptor associated kinase 4 (IRAK-4) inhibitor.

1042224-63-4
DC9492 IRAK inhibitor 2

IRAK inhibitor 2 is interleukin-1 receptor associated kinase inhibitor .

928333-30-6
DC10584 IRAK4-IN-1 Featured

IRAK4-IN-1 is an interleukin-1 receptor associated kinase 4 (IRAK4) inhibitor with an IC50 of 7 nM.

1820787-94-7
DC11185 PF-06426779

PF-06426779 (PF06426779) is a potent, selective IRAK4 inhibitor with IC50 of 1 nM against full-length IRAK4 kinase and cell-based IC50 of 12 nM.

1817628-40-2
DC28331 IRAK4-IN-4

IRAK4-IN-4 is an interleukin-1 receptor–associated kinase 4 (IRAK4) inhibitor extracted from patent CN107163044A, Compound15, has an IC50 of 2.8 nM. IRAK4-IN-4 also inhibits cyclic GMP-AMP synthase (cGAS) with an IC50 of 2.1 nM.

1850276-58-2
DC31041 BMS-986126

BMS-986126 is a potent, highly selective inhibitor of IRAK4 kinase with IC50 of 5.3 nM, displays >100-fold selective for IRAK4 over a panel of 214 kinases.

DC40037 JH-X-119-01 hydrochloride

JH-X-119-01 hydrochloride is a potent and selective interleukin-1 receptor-associated kinases 1 (IRAK1) inhibitor. JH-X-119-01 hydrochloride ameliorates LPS-induced sepsis in mice.

DC40577 IRAK inhibitor 4

IRAK inhibitor 4 is an interleukin-1 receptor associated kinase 4(IRAK4) inhibitor.

1012104-68-5
DC42322 HS271

HS271 is a highly potent, orally active and selective IRAK4, with an IC50 of 7.2 μM. HS271 exhibits superior enzymatic and cellular activities, as well as excellent pharmacokinetic properties.

2410393-15-4
DC42505 IRAK-4 protein kinase inhibitor 2

IRAK-4 protein kinase inhibitor 2 (compound 1) is a potent inhibitor of interleukin-1 (IL-1) receptor-associated kinase-4 (IRAK-4), with an IC50 of 4 μM. IRAK-4 protein kinase inhibitor 2 can be used for the research of inflammatory and immune-related conditions or disorders.

301675-24-1
DC46171 PROTAC IRAK4 degrader-5

PROTAC IRAK4 degrader-5 is a PROTAC-based IRAK4 degrader extracted from patent US20190192668A1, compound I-171.

2360530-61-4
DC47009 Zabedosertib

Zabedosertib (BAY 1834845) is a IRAK4 inhibitor with immunomodulatory potential. IRAK4 is a protein kinase involved in signaling innate immune responses from Toll-like receptors.

1931994-81-8
DC49667 IRAK4-IN-8

IRAK4-IN-8 (VI-177) is a potent IRAK4 inhibitor.

2033070-97-0
DC70435 GNE-2256

GNE-2256 (GNE2256) is a potent, selective inhibitor of IRAK4 with biochemical Ki of 1.4 nM.GNE-2256 displays high selectivity in the CEREP panel with off-targets with >50% inhibition are TACR1, HTR2B and ACHE.GNE-2256 is potent in the NanoBRET assay (IC50 = 3.3 nM), the IL-6 human whole blood assay (IC50=190 nM) and the IFNα human whole blood assay (IC50=290 nM).

2102170-43-2
DC70493 HS-243

HS-243 (HS243) is a highly potent, super-selective IRAK-1/4 inhibitor with IC50 of 24/20 nM, respectively.HS-243 shows exquisite potency toward IRAK-1/4 over all other human kinases with only minimal TAK1-inhibiting activity (IC50=0.5 uM).HS-243 binds in the ATP-binding pocket of IRAK-4.HS-243 potently reduces the proinflammatory response of RA cells and macrophages, has distinct cytokine profile from TAK1.HS-243 reduces percentage of survival in pancreatic and breast cancer cell lines.

848249-10-5
DC70644 ND2158

ND2158 (ND-2158) is a highly potent and selective IRAK4 inhibitor with IC50 of 1.3 nM; ND2158 demonstrates high selectivity against 334 kinases, and >1000-fold over IRAK1. ND2158 blocked TNF production, collagen-induced arthritis, and gout formation in mice, suppressed LPS-induced TNF production, alleviated collagen-induced arthritis, and blocked gout formation in mouse models. IRAK4 inhibition promoted killing of ABC DLBCL lines harboring MYD88 L265P, by down-modulating survival signals, including NF-κB and autocrine IL-6/IL-10 engagement of the JAK-STAT3 pathway. In ABC DLBCL xenograft models, IRAK4 inhibition suppressed tumor growth as a single agent, and in combination with the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib or the Bcl-2 inhibitor ABT-199.

1388896-07-8
DC70845 THZ-2-118

THZ-2-118 is a potent selective inhibitor of IRAK1 with IC50 of 14.2 nM; THZ-2-118 does not inhibitor IRAK4 at 10 uM, also potently inhibits JNK1/2/3 (IC50=1-2 nM).

1644498-54-3
Page 1 / Total 1 FirstPrevNextLastGoto